243,288 Shares in Stryker Corporation $SYK Acquired by EP Wealth Advisors LLC

EP Wealth Advisors LLC acquired a new stake in Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 243,288 shares of the medical technology company’s stock, valued at approximately $76,597,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Sankala Group LLC bought a new position in shares of Stryker in the fourth quarter valued at $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker during the third quarter worth about $27,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker during the fourth quarter worth about $26,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the 4th quarter worth about $27,000. Finally, Gables Capital Management Inc. acquired a new stake in shares of Stryker in the 2nd quarter worth about $25,000. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.7%

NYSE:SYK opened at $329.86 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The stock’s fifty day moving average price is $326.99 and its two-hundred day moving average price is $332.64. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market cap of $126.52 billion, a P/E ratio of 34.18, a P/E/G ratio of 2.09 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the previous year, the business earned $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is currently 36.48%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 665,370 shares of company stock valued at $216,238,501. 4.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

SYK has been the subject of a number of analyst reports. Truist Financial lifted their price target on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday, May 1st. Barclays dropped their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, BTIG Research lowered their price target on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $386.28.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.